Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

Core Insights - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections [1][2] - The company will present at the Viruses of Microbes 2024 conference, highlighting advancements in bacteriophage therapy from discovery to clinical trials [1] Company Overview - Armata is advancing a broad pipeline of natural and synthetic phage candidates targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus [2] - The company utilizes proprietary bacteriophage-based technology and has in-house cGMP manufacturing capabilities for drug development [2]